Corneal endothelium and growth factors

Hoppenreijs, V. P. T.; Pels, Elisabeth; Vrensen, Gijs F.J.M.; Treffers, W. F.

doi:10.1016/s0039-6257(96)80005-1

Cited by 53 publications

(34 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the mammalian eyes, EGF is one of the biologically most potent and best characterized growth factors: it stimulates proliferation, chemotaxis/migration and wound healing of epithelial cells and keratocytes of animal and human species (Imanishi et al 2000, Hoppenreijs et al 1996.…”

Section: Discussionmentioning

confidence: 99%

The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane

Russo¹,

Bonci²,

Bonci³

2011

Cell Tissue Bank

View full text Add to dashboard Cite

The aim of this work is to quantify the total protein and growth factors content in a tissue-suspension obtained from processed human amniotic membrane (hAM). hAM was collected, frozen, freeze dried, powdered and sterilized by γ-irradiation. At each step of the process, samples were characterized for the total protein amounts by a Bradford protein assay and for the growth factor concentrations by ELISA test of the tissue suspensions. Frozen-hAM samples show higher release of total proteins and specific growth factors in the tissue suspension in comparison with freeze-dried hAM. We observed that even if the protein extraction is hindered once the tissue is dried, the powdering process allows a greater release in the tissue suspension of total proteins and growth factors after tissue re-solubilization in comparison with only the freeze-drying process (+91 ± 13% for EGF, +16 ± 4% for HGF, +11 ± 5% for FGF, +16 ± 9% for TGF-β1), and a greater release of EGF (85 ± 10%) in comparison with only the freezing process, because proteins become much readily solubilized in the solution. According with these results, we describe a protocol to obtain a new sterile biological product from hAM tissue, with well-known effects of thermal, mechanical and physical processes on the total protein and grow factors contents.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane

Russo¹,

Bonci²,

Bonci³

2011

Cell Tissue Bank

View full text Add to dashboard Cite

show abstract

“…The importance of the linear disruptions may be limited since no adjacent cell death was observed and the streaks could no longer be detected after an additional week of organ culture. 23,24 Since the efficacy of the endothelial cell pump depends on the presence of tight junctions (zonula occludens) between the cell borders, persistent intercellular disruptions potentially compromise graft function. However, if the disruption of the intercellular junctions is restored quickly, the damage induced by surgical preparation of a Descemet graft may be of minor concern for the short-term performance of the graft as well as for long-term graft survival.…”

Section: Discussionmentioning

confidence: 99%

Donor tissue preparation for Descemet membrane endothelial keratoplasty

Lie

Birbal

Ham

et al. 2008

Journal of Cataract and Refractive Surgery

236

129

View full text Add to dashboard Cite

show abstract

“…Our group, as well as several other groups, reported that pharmaceutical agents such as epidermal growth factor, platelet-derived growth factor, FGF-2, and small interfering RNA of connexin 43 showed the potent effect of enhancing the promotion of corneal endothelial cells, both in vitro and in vivo. [10][11][12] However, a pharmaceutical agent has yet to be introduced into the clinical setting. 1,13 In a previous study, we demonstrated that a specific Rho kinase (ROCK)-inhibitor, Y-27632, increased the proliferative potential of cultivated primate CECs in vitro.…”

Section: Purposementioning

confidence: 99%

The ROCK Inhibitor Eye Drop Accelerates Corneal Endothelium Wound Healing

Okumura

Koizumi

Kay

et al. 2013

Invest. Ophthalmol. Vis. Sci.

206

166

View full text Add to dashboard Cite

Citation: Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54:243954: -250254: . DOI:10. 1167 PURPOSE. To evaluate the effect of Rho kinase (ROCK)-inhibitor eye drops on a corneal endothelial dysfunction primate model and human clinical case series of corneal endothelial dysfunction.METHODS. As a corneal-endothelial partially injured model, the corneal endothelium of seven cynomolgus monkeys was damaged by transcorneal freezing; 10 mM of ROCK inhibitor Y-27632 was then applied topically 6 times daily. The phenotype of the reconstructed corneal endothelium was evaluated by immunohistochemical analysis and noncontact specular microscopy. For clinical study, the effect of Y-27632 eye drops after transcorneal freezing was evaluated in eight corneal endothelial dysfunction patients: four central corneal edema patients and four diffuse corneal edema patients.RESULTS. Slit-lamp microscopy revealed that both Y-27632-treated and -nontreated corneas became hazy after transcorneal freezing, and then recovered their transparency within 4 weeks. ROCK inhibitor Y-27632 promoted recovery of corneal endothelial cell density and wound healing in terms of both morphology and function. The percentage of ZO-1 and Na þ / K þ -ATPase positive cells in the regenerated area in the Y-27632 group was significantly higher than in the controls. Noncontact specular microscopy revealed that corneal endothelial cell density was significantly higher in the Y-27632 group compared with the controls at 4 weeks; cell density reached approximately 3000 cells/mm 2 , as opposed to 1500 cells/mm 2 in the control group. In addition to the animal study findings, the clinical study findings showed that Y-27632 eye drops effectively improved corneal edema of corneal endothelial dysfunction patients with central edema. 2 However, several severe problems can arise associated with corneal transplantation, including allograft rejection, primary graft failure, and severe loss of cell density. To the best of our knowledge, no clinically practical medical therapy has been developed to effectively treat corneal endothelial dysfunction.As an alternative to corneal transplantation, regenerative medical procedures might be a plausible path of therapy for treating severe corneal endothelial dysfunction. Several research groups, including ours, have reported transplantations of cultivated CECs in an animal model to establish a new clinical intervention for corneal endothelial dysfunction. [3][4][5][6][7][8][9] We recently reported the use of cell therapy to successfully achieve the recovery of corneal transparency in both rabbit and primate corneal endothelial dysfunction models. 9 However, in cases of early-stage corneal endothelial dysfunction, in which stem cells or progenitor cells are still maintained in the tissue, drug therapy may provide a less-invasive or antiprogression treatment. Our group, as well as several other groups, reported that pharmaceutical agents such...

show abstract

Corneal endothelium and growth factors

Cited by 53 publications

References 84 publications

The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane

The effects of different preservation processes on the total protein and growth factor content in a new biological product developed from human amniotic membrane

Donor tissue preparation for Descemet membrane endothelial keratoplasty

The ROCK Inhibitor Eye Drop Accelerates Corneal Endothelium Wound Healing

Contact Info

Product

Resources

About